"The central government is satisfied that the use of serodiagnostic test kits for diagnosis of tuberculosis are giving inconsistent and improper results leading to wrong diagnosis and their use is likely to involve risk to human beings and whereas safer alternatives are available," said a notification issued by the Ministry of Health and Family Welfare.
The Ministry held that "it is necessary and expedient to prohibit the manufacture, sale, distribution and use of the said test kits in public interest."
The test kits have been banned with immediate effect following exercise of powers conferred by Section 26A of the Drugs and Cosmetic Act, 1940.
The ban follows a negative policy statement issued by the WHO over commercial serodiagnostic tests for tuberculosis stating that "commercial serological tests provide inconsistent and imprecise findings resulting in highly variable values for sensitivity and specificity."
The government had also sent a warning to various states for not using the serodiagnostic tests due to their inaccurate results.
"There is no evidence that existing commercial serological assays improve patient-important outcomes, and high proportions of false-positive and false-negative results adversely impact patient safety. Overall data quality was graded as very low and it is strongly recommended that these tests not be used for the diagnosis of pulmonary and extra- pulmonary TB," the WHO policy statement concluded.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
